Summary:
When developing patient-centric products for biologics, different doses, expressed by different combinations of volume/concentration may require different delivery devices. As a result, it takes a great deal of time and effort in planning and coordinating the formulation and device activities. In this podcast, Pharma and Drug Delivery executives from Nanoform, Pfizer, GSK, Takeda and Kymanox discuss how they facilitate partnerships between drug product development, device engineering and clinical study teams to determine how to balance concentration and volume and develop optimal devices for delivery and commercialization. Specifically:- Impact on increasing concentration of drugs on deliverability
- Technical feasibility of manufacturing larger volume devices
- Patient tolerability and human factors that impact patient adherence
This panel discussion was recorded at the October 2024 PODD: Partnership Opportunities in Drug Delivery conference. For more information, go to Drug-Delivery.org.
Moderators
Christian Jones
Chief Commercial Officer
Nanoform
Panelists
E Guan, PhD
Head of Injection Systems
Takeda
Lindsey Crawford, PhD
Senior Principal Scientist
Pfizer
Dany Doucet, PhD
Director of the Early Engagement and Deviceability
GSK
Nicholas Schill, PhD
Senior Director, Landscaping & Platform Definition; Device & Combination Product Development
AbbVie
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.